Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 9.29 -2.62% -0.25
XENE closed down 2.62 percent on Monday, May 20, 2019, on 34 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical XENE trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Inside Day Range Contraction 0.00%
200 DMA Resistance Bearish -2.62%
20 DMA Support Bullish -2.62%
Crossed Above 50 DMA Bullish -2.62%
Bollinger Band Squeeze Range Contraction -2.62%

Older signals for XENE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Chemistry Biopharmaceutical Pain Chemical Compounds Organic Compounds Gene Therapy Acne Osteoarthritis Cardiovascular Disease Analgesics Genentech Treatment Of Osteoarthritis Indoles Lipoprotein Lipase Deficiency Alipogene Tiparvovec Glybera Postherpetic Neuralgia
Is XENE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.92
52 Week Low 5.25
Average Volume 92,912
200-Day Moving Average 9.6044
50-Day Moving Average 9.477
20-Day Moving Average 9.269
10-Day Moving Average 9.246
Average True Range 0.5367
ADX 15.84
+DI 22.3479
-DI 13.1159
Chandelier Exit (Long, 3 ATRs ) 8.3899
Chandelier Exit (Short, 3 ATRs ) 9.8401
Upper Bollinger Band 9.7729
Lower Bollinger Band 8.7651
Percent B (%b) 0.52
BandWidth 10.872802
MACD Line -0.0188
MACD Signal Line -0.0438
MACD Histogram 0.025
Fundamentals Value
Market Cap 167.19 Million
Num Shares 18 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -5.60
Price-to-Sales 65.85
Price-to-Book 1.07
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.98
Resistance 3 (R3) 10.04 9.88 9.87
Resistance 2 (R2) 9.88 9.70 9.85 9.83
Resistance 1 (R1) 9.58 9.59 9.50 9.52 9.79
Pivot Point 9.42 9.42 9.38 9.39 9.42
Support 1 (S1) 9.12 9.24 9.04 9.06 8.79
Support 2 (S2) 8.96 9.13 8.93 8.75
Support 3 (S3) 8.66 8.96 8.72
Support 4 (S4) 8.60